CTI BioPharma Cash Flow Statement

Financials in millions CAD. Fiscal year is June - May.

Millions CAD. Fiscal year is Jun - May.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '25 Feb 28, 2025	May '24 May 31, 2024	May '23 May 31, 2023	May '22 May 31, 2022	May '21 May 31, 2021	May '20 May 31, 2020
Net Income	-1.99	-3.46	-24.54	-20.52	-16.43	-0.15
Depreciation & Amortization	0.32	0.37	0.37	0.3	1.58	-
Loss (Gain) From Sale of Assets	0.03	-0.05	-	-	-	-
Asset Writedown & Restructuring Costs	-	-	34.52	-	-	-
Stock-Based Compensation	0.42	0.62	3.03	9.8	2.8	0.03
Other Operating Activities	-0.32	0.22	-17.04	-0.01	9.66	-
Change in Accounts Receivable	0.08	0.13	-0.1	0.03	-0.07	-0
Change in Accounts Payable	-0.87	2.52	1.32	0.96	0.1	0.03
Change in Unearned Revenue	3.78	-0.14	0.16	-	-	-
Change in Other Net Operating Assets	-0.22	-0.38	0.26	-0.27	-0.76	-
Operating Cash Flow	1.22	-0.16	-2.01	-9.71	-3.13	-0.1
Capital Expenditures	-0.01	-0.01	-0.06	-0.62	-0.2	-0.08
Sale of Property, Plant & Equipment	0.05	0.06	-	-	-	-
Cash Acquisitions	-	-	0.02	-	-	-
Investing Cash Flow	0.04	0.05	-0.04	-0.62	-0.2	-0.08
Short-Term Debt Issued	-	0.48	0.7	-	-	-
Total Debt Issued	0.01	0.48	0.7	-	-	-
Long-Term Debt Repaid	-	-0.4	-0.39	-0.26	-	-
Net Debt Issued (Repaid)	-0.6	0.08	0.31	-0.26	-	-
Issuance of Common Stock	-	-	1.27	9.91	4.85	0.81
Other Financing Activities	-	-	-0.11	-0.57	-0.16	0.43
Financing Cash Flow	-0.6	0.08	1.47	9.09	4.69	1.24
Foreign Exchange Rate Adjustments	0.05	-0.02	0.01	-0.02	-0	-
Net Cash Flow	0.71	-0.05	-0.57	-1.27	1.36	1.06
Free Cash Flow	1.21	-0.17	-2.07	-10.33	-3.33	-0.18
Free Cash Flow Per Share	0.01	-0.00	-0.02	-0.12	-0.08	-0.01
Levered Free Cash Flow	1.3	1.02	0.74	0.45	-5.89	-
Unlevered Free Cash Flow	1.45	1.18	0.87	0.55	-5.89	-
Change in Net Working Capital	-2.17	-2.3	-1.91	-0.41	0.73	-

Updated Jan 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.